VivoSeq
Infectious Disease

Chronic Hepatitis B

5

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

Chronic Hepatitis b is an early-stage landscape with 5 programs across 5 companies. The most active players are Shanghai Argo Biopharmaceutical Co., Ltd., Eli Lilly, GSK. 3 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shanghai Argo Biopharmaceutical Co., Ltd.

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1GSK logo

GSK

1 program

Phase 3L

Lee's Pharmaceutical Limited

1 program

ApprovedGilead logo

Gilead

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

2programs
Small molecule150%
RNA therapy150%

Modality classified for 50% of 6 pipeline programs.

Analysis

Trial Status

6

clinical trials

Completed4 · 67%
Not yet recruiting1 · 17%
Recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection
Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Approved·NCT07573943·150 enrolled
A Study on the Consistency Evaluation of Digital PCR Technology for Quantitative Detection of Hepatitis B Virus Nucleic Acid
Not yet recruiting·BBeijing Municipal Administration of Hospitals·N/A·NCT07684209·200 enrolled
Withdrawal of Therapy After Long-Term Oral Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT01581554·15 enrolled
Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 1)
Completed·GSK logoGSK·Phase 3·NCT05630807·981 enrolled
Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 2)
Completed·GSK logoGSK·Phase 3·NCT05630820·857 enrolled
A Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Chinese Healthy Subjects and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity in Chinese Subjects With Chronic HBV Infection
Completed·SShanghai Argo Biopharmaceutical Co., Ltd.·Phase 1·NCT07595159·32 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)